|

Trastuzumab Biosimilar Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Hercessi®, Herzuma®, Kanjinti®, Ogivri®, Ontruzant® +1 more

Pipeline

Phase 1/2: 1

Top Sponsors

  • Merck Sharp & Dohme LLC1

Indications

  • Breast Neoplasms1
  • Breast Cancer1
  • Cancer1

Boston, Massachusetts1 trial

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Dana-Farber Cancer Institute ( Site 0050)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.